551 related articles for article (PubMed ID: 15344561)
1. [Advancements in PSA-based screening for prostate cancer].
Ito K
Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
[TBL] [Abstract][Full Text] [Related]
2. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
3. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
5. Does PSA velocity predict prostate cancer in pre-screened populations?
Schröder FH; Roobol MJ; van der Kwast TH; Kranse R; Bangma CH
Eur Urol; 2006 Mar; 49(3):460-5; discussion 465. PubMed ID: 16442212
[TBL] [Abstract][Full Text] [Related]
6. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
[TBL] [Abstract][Full Text] [Related]
7. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis of cancer of the prostate (I): Advancements in knowledge and practice since the consensus conference of 1989. The "Cancer of the Prostate" subcommittee of the Committee of Oncology of the French Association of Urology].
Villers A; Grosclaude P; Haillot O; Abbou CC; Richard F; Boccon-Gibod L
Prog Urol; 1997 Jun; 7(3):508-15. PubMed ID: 9273082
[TBL] [Abstract][Full Text] [Related]
9. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
10. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
[TBL] [Abstract][Full Text] [Related]
11. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
[TBL] [Abstract][Full Text] [Related]
12. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
13. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
[TBL] [Abstract][Full Text] [Related]
14. [Value of determining prostate-specific antigen for early detection or prostatic carcinoma].
Hammerer P; Huland H
Urologe A; 1995 Jul; 34(4):283-9. PubMed ID: 7545842
[TBL] [Abstract][Full Text] [Related]
15. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
Bourel M; Ardaillou R;
Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
[TBL] [Abstract][Full Text] [Related]
16. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
18. [Prostate cancer screening].
Villers A; Rébillard X; Soulié M; Davin JL; Coloby P; Moreau JL; Mejean A; Irani J; Coulange C; Mangin P;
Prog Urol; 2003 Apr; 13(2):209-14. PubMed ID: 12765053
[TBL] [Abstract][Full Text] [Related]
19. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
Kamoi K; Babaian RJ
Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]